Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. develops and commercializes therapies for rare neuroendocrine diseases, centered on IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity linked to rare MC4R pathway disorders. Company updates commonly cover U.S. and international commercialization of setmelanotide, regulatory authorizations and label expansions for acquired hypothalamic obesity, Bardet-Biedl syndrome, POMC/PCSK1 deficiency and LEPR deficiency, and safety information tied to approved uses.
Rhythm news also follows clinical data from setmelanotide studies, including acquired hypothalamic obesity and genetically caused MC4R pathway diseases, along with development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism. Recurring corporate items include financial results, specialty-pharmacy access arrangements, healthcare conference presentations and board governance changes.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update. Participants can register for the call online and are encouraged to join 10 minutes early.
An archived webcast will be posted under “Events and Presentations” in the Investor Relations section of Rhythm’s website about two hours after the call and remain available for 30 days. Rhythm is a commercial-stage biopharma company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the United States, European Union and United Kingdom for specific forms of acquired hypothalamic obesity and genetically defined syndromic or monogenic obesity, with detailed indications, limitations of use, and important safety information including warnings on hypersensitivity, depression, sexual arousal disturbances, skin hyperpigmentation, adrenal insufficiency, and sodium imbalance.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported that pivotal Phase 3 TRANSCEND trial results of setmelanotide in acquired hypothalamic obesity were published in The New England Journal of Medicine. The 52-week study showed substantial placebo-adjusted BMI reductions, improved hunger scores, and a safety profile without new signals, supporting recent FDA and EU regulatory milestones.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported multiple new data sets for its MC4R agonists setmelanotide and oral bivamelagon in acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS) and Prader-Willi syndrome (PWS) at ENDO 2026.
Highlights include long-term BMI reductions, weight category improvements, real-world weight loss and reduced obesity-related healthcare visits, alongside manageable adverse events.
Rhythm Pharmaceuticals (Nasdaq:RYTM) reported positive interim six‑month data from a Phase 2 trial of setmelanotide in patients with Prader‑Willi syndrome (PWS) presented at ENDO 2026.
Among 17 patients, results showed mean BMI reductions, fat mass loss with preserved lean mass, improved hyperphagia and anxiety measures, and safety consistent with the known profile, supporting advancement to Phase 3.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month Phase 2 results evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
The webcast and 30-day replay will be available in the Investor Relations section under Events and Presentations on the Rhythm Pharmaceuticals website.
Rhythm Pharmaceuticals (Nasdaq:RYTM) will feature seven abstracts, including four late-breaking, at ENDO 2026 on June 13‑16 in Chicago.
Presentations cover setmelanotide and oral bivamelagon in Prader‑Willi syndrome, acquired hypothalamic obesity, and Bardet‑Biedl syndrome, plus Rhythm’s MOMENTUM expert meeting on June 12.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced publication of a new, evidence-based diagnostic algorithm for Bardet-Biedl syndrome (BBS) in the American Journal of Medical Genetics. Developed by international experts and patient groups, the algorithm integrates updated clinical and genetic insights to support earlier, clinically based BBS diagnosis across all ages and presentations.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced management participation in two upcoming healthcare investor conferences. CFO Hunter Smith will join a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 p.m. ET.
CEO David Meeker will speak at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 1:20 p.m. ET. Both webcasts and 30-day replays will be accessible via the company’s Investor Relations webpage under “Events & Presentations”.
Rhythm Pharmaceuticals (Nasdaq:RYTM) will present six posters, including four with new data, on setmelanotide at the 2026 European Congress of Endocrinology in Prague.
Highlights include real-world BMI reductions in acquired hypothalamic obesity, Phase 3 cardiometabolic index improvements, underrecognized hyperphagia in Bardet-Biedl syndrome, and the lifelong burden of acquired hypothalamic obesity after craniopharyngioma.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that David Meeker, M.D., Chairman, President and CEO, will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13, 2026 at 3:00 p.m. PT in Las Vegas.
The event will be webcast and available under Events & Presentations in the company Investor Relations site, with a replay available on the Rhythm website for 30 days.